Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CaplytaIndication |
schizophrenia
bipolar depression |
| gptkbp:CEO |
Sharon Mates
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
neurological disorders
central nervous system disorders psychiatric disorders |
| gptkbp:foundedYear |
2002
|
| gptkbp:founder |
Sharon Mates
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
Caplyta
|
| gptkbp:numberOfEmployees |
~500 (as of 2023)
|
| gptkbp:product |
Caplyta
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchArea |
CNS drug development
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ITCI
|
| gptkbp:website |
https://www.intracellulartherapies.com/
|
| gptkbp:bfsParent |
gptkb:Sol_Barer
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Intra-Cellular Therapies
|